联合或单药ipilimumab作为晚期黑色素瘤的免疫治疗:一个重要的回顾。

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2016-09-01 Epub Date: 2016-08-22 DOI:10.2217/mmt-2016-0011

Omar Abdel-Rahman

{"title":"联合或单药ipilimumab作为晚期黑色素瘤的免疫治疗:一个重要的回顾。","authors":"Omar Abdel-Rahman","doi":"10.2217/mmt-2016-0011","DOIUrl":null,"url":null,"abstract":"Aim: A pooled analysis of the efficacy and toxicity of combination immunotherapy versus single-agent ipilimumab in the management of advanced melanoma has been conducted.Methodology: Eligible studies included randomized controlled studies evaluating ipilimumab-based doublet immunotherapy versus ipilimumab monotherapy for the management of unresectable melanoma.Results: Nivolumab/ipilimumab combination strategy is associated with a significant improvement in objective response rate (odds ratio: 7.38; 95% CI: 3.71-14.67; p < 0.00001) and progression-free survival (0.42; 95% CI: 0.34-0.52; p < 0.00001) as well as a higher relative risk for high-grade elevated alanine aminotransferase (5.58; 95% CI: 2.28-13.67; p = 0.0002).Conclusion: This analysis demonstrated that nivolumab/ipilimumab combination is associated with a higher objective response rate and progression-free survival in the management of advanced melanoma.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":"3 3","pages":"231-243"},"PeriodicalIF":1.0000,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2016-0011","citationCount":"4","resultStr":"{\"title\":\"Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review.\",\"authors\":\"Omar Abdel-Rahman\",\"doi\":\"10.2217/mmt-2016-0011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: A pooled analysis of the efficacy and toxicity of combination immunotherapy versus single-agent ipilimumab in the management of advanced melanoma has been conducted.Methodology: Eligible studies included randomized controlled studies evaluating ipilimumab-based doublet immunotherapy versus ipilimumab monotherapy for the management of unresectable melanoma.Results: Nivolumab/ipilimumab combination strategy is associated with a significant improvement in objective response rate (odds ratio: 7.38; 95% CI: 3.71-14.67; p < 0.00001) and progression-free survival (0.42; 95% CI: 0.34-0.52; p < 0.00001) as well as a higher relative risk for high-grade elevated alanine aminotransferase (5.58; 95% CI: 2.28-13.67; p = 0.0002).Conclusion: This analysis demonstrated that nivolumab/ipilimumab combination is associated with a higher objective response rate and progression-free survival in the management of advanced melanoma.\",\"PeriodicalId\":44562,\"journal\":{\"name\":\"Melanoma Management\",\"volume\":\"3 3\",\"pages\":\"231-243\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2016-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/mmt-2016-0011\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Melanoma Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/mmt-2016-0011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2016/8/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/mmt-2016-0011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/8/22 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 4

摘要

目的:对联合免疫治疗与单药伊匹单抗治疗晚期黑色素瘤的疗效和毒性进行了汇总分析。方法:符合条件的研究包括随机对照研究，评估基于伊匹单抗的双重免疫治疗与伊匹单抗单药治疗对不可切除黑色素瘤的治疗。结果:纳武单抗/伊匹单抗联合策略与客观缓解率的显著改善相关(优势比:7.38;95% ci: 3.71-14.67;P < 0.00001)和无进展生存期(0.42;95% ci: 0.34-0.52;P < 0.00001)，以及高水平谷丙转氨酶升高的相对风险(5.58;95% ci: 2.28-13.67;P = 0.0002)。结论:该分析表明，nivolumab/ipilimumab联合治疗晚期黑色素瘤具有更高的客观缓解率和无进展生存期。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review.

查看原文本刊更多论文

Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review.

Aim: A pooled analysis of the efficacy and toxicity of combination immunotherapy versus single-agent ipilimumab in the management of advanced melanoma has been conducted.

Methodology: Eligible studies included randomized controlled studies evaluating ipilimumab-based doublet immunotherapy versus ipilimumab monotherapy for the management of unresectable melanoma.

Results: Nivolumab/ipilimumab combination strategy is associated with a significant improvement in objective response rate (odds ratio: 7.38; 95% CI: 3.71-14.67; p < 0.00001) and progression-free survival (0.42; 95% CI: 0.34-0.52; p < 0.00001) as well as a higher relative risk for high-grade elevated alanine aminotransferase (5.58; 95% CI: 2.28-13.67; p = 0.0002).

Conclusion: This analysis demonstrated that nivolumab/ipilimumab combination is associated with a higher objective response rate and progression-free survival in the management of advanced melanoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.